Get the Stockscreener App
1.44
5.11%
0.07
After Hours:
1.42
-0.02
-1.39%
Cardiol Therapeutics Inc stock is traded at $1.44, with a volume of 204.62K.
It is up +5.11% in the last 24 hours and down -5.88% over the past month.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
See More
Previous Close:
$1.37
Open:
$1.41
24h Volume:
204.62K
Relative Volume:
0.43
Market Cap:
$117.51M
Revenue:
-
Net Income/Loss:
$-21.65M
P/E Ratio:
-4.336
EPS:
-0.3321
Net Cash Flow:
$-15.84M
1W Performance:
+9.92%
1M Performance:
-5.88%
6M Performance:
-25.00%
1Y Performance:
+63.62%
1-Day Range:
$1.375
$1.4568
1-Week Range:
$1.23
$1.46
52-Week Range:
$0.8778
$3.12
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.44 | 117.51M | 0 | -21.65M | -15.84M | -0.3321 |
|
ZTS
Zoetis Inc
|
163.31 | 73.68B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.46 | 42.77B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.26 | 42.04B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.24 | 24.07B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.28 | 14.66B | 15.05B | -883.30M | 1.89B | -0.74 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-24 | Initiated | ROTH MKM | Buy |
| Apr-22-24 | Initiated | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Stock (CRDL) Latest News
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Short Interest Up 12.4% in December - MarketBeat
Appendix 3Y x4 - Investing News Network
Cardiol Therapeutics Sees Insider Buying From Leadership Team And Board Members - The Deep Dive
Guillermo Torre Purchases 17,240 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) Stock - MarketBeat
Insider Buying: Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Buys 18,900 Shares of Stock - MarketBeat
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive financial news
HC Wainwright Has Positive Forecast for CRDL FY2024 Earnings - Defense World
FY2024 Earnings Forecast for CRDL Issued By HC Wainwright - MarketBeat
RAD 202 receives approval to start Phase 1 therapeutic trial - Investing News Network
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis - The Manila Times
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis - Investing News Network
PRISM MarketView Features Q&A with President and CEO David - GlobeNewswire
HC Wainwright Reiterates Buy Rating for Cardiol Therapeutics (NASDAQ:CRDL) - MarketBeat
Cardiex Completes Placement Ahead of CONNEQT US Launch - Investing News Network
BPH Global receives funding commitment of A$100,000 - Investing News Network
Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Bernard Lim Acquires 10,000 Shares of Stock - MarketBeat
David Elsley Buys 40,000 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) Stock - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Down 2.1%What's Next? - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Down 2.1% – Here’s What Happened - Defense World
Townsquare Capital LLC Buys New Shares in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics (STU:CT9) Momentum Rank : 6 (As of Dec. 05, 2024) - GuruFocus.com
Cardiol Therapeutics (OTCMKTS:CRTPF) Shares Down 3.1% – Should You Sell? - Defense World
Cardiol Therapeutics (TSX:CRDL) Price-to-Operating-Cash-Flo - GuruFocus.com
CRDL (Cardiol Therapeutics) 50-Day SMA : $1.88 (As of Dec. 01, 2024) - GuruFocus.com
Cardiol Therapeutics (TSX:CRDL) Enterprise Value : C$168.30 Mil (As of Dec. 01, 2024) - GuruFocus.com
Cardiol Therapeutics (FRA:CT9) Price-to-Free-Cash-Flow : N/A (As of Dec. 01, 2024) - GuruFocus.com
3 Penny Stocks Ready to Break Out in 2025 - MarketBeat
3 Penny Stocks Ready To Break Out In 2025 - Barchart
Cardiol Therapeutics (CRDL-Q) QuotePress Release - The Globe and Mail
Cardiol Therapeutics (FRA:CT9) Cyclically Adjusted Revenue per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
Game-Changing Solution for Heart Inflammation? | David Elsley – Cardiol Therapeutics - The Deep Dive
HC Wainwright Issues Optimistic Estimate for CRDL Earnings - Defense World
Comparing Cardiol Therapeutics (NASDAQ:CRDL) & Gilead Sciences (NASDAQ:GILD) - Defense World
What is HC Wainwright's Forecast for CRDL FY2024 Earnings? - MarketBeat
Equities Analysts Set Expectations for CRDL FY2024 Earnings - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Earns Buy Rating from HC Wainwright - Defense World
Cardiol Therapeutics (TSE:CRDL) Shares Up 1.8%What's Next? - MarketBeat
Leede Financial Issues Positive Forecast for CRDL Earnings - Defense World
Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug - openPR
What is Leede Financial’s Estimate for CRDL FY2027 Earnings? - Defense World
What is Leede Financial's Forecast for CRDL FY2024 Earnings? - MarketBeat
Roth Capital Has Negative Outlook for CRDL FY2024 Earnings - MarketBeat
Biotech Initiates Phase III Trial for Heart Disease Drug - Streetwise Reports
Pericarditis Drugs Market Is Expected To Reach $816.6 Million - openPR
Cardiol Therapeutics (NASDAQ:CRDL) Given Buy Rating at HC Wainwright - MarketBeat
What is Leede Financial's Forecast for CRDL FY2027 Earnings? - MarketBeat
CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study - Benzinga
Analyst Says Biotech's Data Supports Advancement Into Phase III - Streetwise Reports
Five Top Heart Health Stocks to Buy Heading into 2025 - Baystreet.ca
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLMA Must-Watch This Week! - openPR
Cardiol Therapeutics Inc. - Baystreet.ca
Cardiol Therapeutics Inc Stock (CRDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.58%
2.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):